UA81300C2 - Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture - Google Patents

Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture Download PDF

Info

Publication number: UA81300C2
Authority: UA; Ukraine
Prior art keywords: tetrahydropyridine; phenyl; hydrogen; halogen; alk
Prior art date: 2003-04-04

Application number

UAA200508779A

Other languages

English (en)

Ukrainian (uk)

Inventor

Ask Puschl

Benny Bang-Andersen

Thomas Ruhland

Kim Andersen

Jan Kehler

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-04

Filing date

2004-02-04

Publication date

2007-12-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA81300(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-02-04 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2007-12-25 Publication of UA81300C2 publication Critical patent/UA81300C2/uk

Links

QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title description 30
229940076279 serotonin Drugs 0.000 title description 5
239000003340 retarding agent Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 125
238000011282 treatment Methods 0.000 claims abstract description 23
208000019906 panic disease Diseases 0.000 claims abstract description 16
208000019022 Mood disease Diseases 0.000 claims abstract description 9
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims abstract description 9
239000001257 hydrogen Substances 0.000 claims description 129
229910052739 hydrogen Inorganic materials 0.000 claims description 129
150000002431 hydrogen Chemical class 0.000 claims description 79
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 74
-1 C1-6C-Alkoxy Chemical class 0.000 claims description 65
229910052736 halogen Inorganic materials 0.000 claims description 59
150000002367 halogens Chemical class 0.000 claims description 58
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 40
125000001424 substituent group Chemical group 0.000 claims description 37
238000000034 method Methods 0.000 claims description 34
150000003839 salts Chemical class 0.000 claims description 22
125000004093 cyano group Chemical group *C#N 0.000 claims description 20
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
125000005842 heteroatom Chemical group 0.000 claims description 14
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
206010041250 Social phobia Diseases 0.000 claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
229910052757 nitrogen Inorganic materials 0.000 claims description 13
125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 11
208000035475 disorder Diseases 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
229940126601 medicinal product Drugs 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 9
208000011688 Generalised anxiety disease Diseases 0.000 claims description 8
206010034912 Phobia Diseases 0.000 claims description 8
208000029364 generalized anxiety disease Diseases 0.000 claims description 8
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
208000008811 Agoraphobia Diseases 0.000 claims description 7
206010033664 Panic attack Diseases 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
201000001716 specific phobia Diseases 0.000 claims description 7
125000000623 heterocyclic group Chemical group 0.000 claims description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
PUEZOCGQEOXEFL-UHFFFAOYSA-N 4-(5-fluoro-2-phenylsulfanylphenyl)-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(F)=CC=C1SC1=CC=CC=C1 PUEZOCGQEOXEFL-UHFFFAOYSA-N 0.000 claims description 3
GWOIXIXFXJRSEE-UHFFFAOYSA-N 4-[2-(2-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC=CC=C1SC1=CC=CC=C1C1=CCNCC1 GWOIXIXFXJRSEE-UHFFFAOYSA-N 0.000 claims description 3
BVFBNCRYXIKJMP-UHFFFAOYSA-N 4-[2-(3-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC=CC(SC=2C(=CC=CC=2)C=2CCNCC=2)=C1 BVFBNCRYXIKJMP-UHFFFAOYSA-N 0.000 claims description 3
XOWCKPZUHHALSB-UHFFFAOYSA-N 4-[2-(4-methylphenyl)sulfanyl-5-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(C)=CC=C1SC1=CC=C(C(F)(F)F)C=C1C1=CCNCC1 XOWCKPZUHHALSB-UHFFFAOYSA-N 0.000 claims description 3
ZGISTZRYULTIMS-UHFFFAOYSA-N 4-[5-fluoro-2-(2-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC=CC=C1SC1=CC=C(F)C=C1C1=CCNCC1 ZGISTZRYULTIMS-UHFFFAOYSA-N 0.000 claims description 3
YRLHHXMJCNCMLO-UHFFFAOYSA-N 4-[5-fluoro-2-(3-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC=CC(SC=2C(=CC(F)=CC=2)C=2CCNCC=2)=C1 YRLHHXMJCNCMLO-UHFFFAOYSA-N 0.000 claims description 3
OILORYGCCZFWTL-UHFFFAOYSA-N 4-[5-fluoro-2-(4-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(C)=CC=C1SC1=CC=C(F)C=C1C1=CCNCC1 OILORYGCCZFWTL-UHFFFAOYSA-N 0.000 claims description 3
ZYRXNMJLYBQAMP-UHFFFAOYSA-N 4-[5-methyl-2-(2-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=CC=C1C ZYRXNMJLYBQAMP-UHFFFAOYSA-N 0.000 claims description 3
JSHLHLNSXPCBPT-UHFFFAOYSA-N 4-[5-methyl-2-(4-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(C)=CC=C1SC1=CC=C(C)C=C1C1=CCNCC1 JSHLHLNSXPCBPT-UHFFFAOYSA-N 0.000 claims description 3
241001465754 Metazoa Species 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
DROZTWRQGIRTLE-UHFFFAOYSA-N 4-[2-(2-bromo-4-fluorophenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=C(F)C=C1Br DROZTWRQGIRTLE-UHFFFAOYSA-N 0.000 claims description 2
HPRWJGRYXXTSLD-UHFFFAOYSA-N 4-[2-(2-bromo-4-methylphenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound BrC1=CC(C)=CC=C1SC1=CC=C(C)C=C1C1=CCNCC1 HPRWJGRYXXTSLD-UHFFFAOYSA-N 0.000 claims description 2
DOGQTRQFXHQXHL-UHFFFAOYSA-N 4-[2-(2-chloro-4-methylphenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound ClC1=CC(C)=CC=C1SC1=CC=C(C)C=C1C1=CCNCC1 DOGQTRQFXHQXHL-UHFFFAOYSA-N 0.000 claims description 2
PHDZOIVGCWIKAA-UHFFFAOYSA-N 4-[2-(3-fluoro-2-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=C(F)C=CC=C1SC1=CC=CC=C1C1=CCNCC1 PHDZOIVGCWIKAA-UHFFFAOYSA-N 0.000 claims description 2
TUVCDLWJOSIGRL-UHFFFAOYSA-N 4-[5-bromo-2-(2,4-dimethylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC(C)=CC=C1SC1=CC=C(Br)C=C1C1=CCNCC1 TUVCDLWJOSIGRL-UHFFFAOYSA-N 0.000 claims description 2
VKUZTLZWFWTBJJ-UHFFFAOYSA-N 4-[2-(2-bromophenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=CC=C1Br VKUZTLZWFWTBJJ-UHFFFAOYSA-N 0.000 claims 1
VPFHQAFQSMMVFA-UHFFFAOYSA-N 4-[2-(2-chlorophenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=CC=C1Cl VPFHQAFQSMMVFA-UHFFFAOYSA-N 0.000 claims 1
WOSFZNBDNYRRPS-UHFFFAOYSA-N 4-[2-(2-fluoro-4-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound FC1=CC(C)=CC=C1SC1=CC=CC=C1C1=CCNCC1 WOSFZNBDNYRRPS-UHFFFAOYSA-N 0.000 claims 1
YUUZWPWDOCQTJZ-UHFFFAOYSA-N 4-[2-(2-fluorophenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=CC=C1F YUUZWPWDOCQTJZ-UHFFFAOYSA-N 0.000 claims 1
QNJYLSDKYNIIRZ-UHFFFAOYSA-N 4-[2-(2-methoxyphenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound COC1=CC=CC=C1SC1=CC=C(C)C=C1C1=CCNCC1 QNJYLSDKYNIIRZ-UHFFFAOYSA-N 0.000 claims 1
BPEKNTQEJVLZHM-UHFFFAOYSA-N 4-[2-(3-chloro-2-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=C(Cl)C=CC=C1SC1=CC=CC=C1C1=CCNCC1 BPEKNTQEJVLZHM-UHFFFAOYSA-N 0.000 claims 1
ZLYAFBWNHUOJMU-UHFFFAOYSA-N 4-[2-(4-chloro-2-fluorophenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=C(Cl)C=C1F ZLYAFBWNHUOJMU-UHFFFAOYSA-N 0.000 claims 1
BQSPIKKONWKLAI-UHFFFAOYSA-N 4-[2-(4-chloro-2-methylphenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=C(Cl)C=C1C BQSPIKKONWKLAI-UHFFFAOYSA-N 0.000 claims 1
VVGLTIBQBCSVQN-UHFFFAOYSA-N 4-[2-(4-fluoro-2-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC(F)=CC=C1SC1=CC=CC=C1C1=CCNCC1 VVGLTIBQBCSVQN-UHFFFAOYSA-N 0.000 claims 1
NBKKRFYFKIWHFQ-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=C(F)C=C1 NBKKRFYFKIWHFQ-UHFFFAOYSA-N 0.000 claims 1
NHJXUHYVMIDBFY-UHFFFAOYSA-N 4-[5-fluoro-2-(4-methoxyphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(OC)=CC=C1SC1=CC=C(F)C=C1C1=CCNCC1 NHJXUHYVMIDBFY-UHFFFAOYSA-N 0.000 claims 1
101000577938 Xenopus laevis Midkine-B Proteins 0.000 claims 1
208000019899 phobic disease Diseases 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
208000019901 Anxiety disease Diseases 0.000 abstract description 5
208000017194 Affective disease Diseases 0.000 abstract 1
HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 26
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
239000000243 solution Substances 0.000 description 19
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 13
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
229910052794 bromium Inorganic materials 0.000 description 10
239000000872 buffer Substances 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
239000003772 serotonin uptake inhibitor Substances 0.000 description 10
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
229910052731 fluorine Inorganic materials 0.000 description 9
239000011737 fluorine Substances 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
239000000203 mixture Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
229940079593 drug Drugs 0.000 description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
229910052740 iodine Inorganic materials 0.000 description 8
239000007787 solid Substances 0.000 description 8
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
125000005322 morpholin-1-yl group Chemical group 0.000 description 7
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 6
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
229910052801 chlorine Inorganic materials 0.000 description 6
239000000460 chlorine Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000007788 liquid Substances 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
230000003287 optical effect Effects 0.000 description 6
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
125000003226 pyrazolyl group Chemical group 0.000 description 6
239000007858 starting material Substances 0.000 description 6
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
241000581652 Hagenia abyssinica Species 0.000 description 5
241000700159 Rattus Species 0.000 description 5
239000000935 antidepressant agent Substances 0.000 description 5
238000010511 deprotection reaction Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
229940126570 serotonin reuptake inhibitor Drugs 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
230000001430 anti-depressive effect Effects 0.000 description 4
229940005513 antidepressants Drugs 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
150000001989 diazonium salts Chemical class 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
238000011534 incubation Methods 0.000 description 4
229960002748 norepinephrine Drugs 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000006187 pill Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000013049 sediment Substances 0.000 description 4
230000000697 serotonin reuptake Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
229960001653 citalopram Drugs 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000006297 dehydration reaction Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
230000000966 norepinephrine reuptake Effects 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000012266 salt solution Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
BMKKDXDTIILJLH-UHFFFAOYSA-N (1-bromocyclohexa-2,4-dien-1-yl)sulfanylbenzene Chemical class C=1C=CC=CC=1SC1(Br)CC=CC=C1 BMKKDXDTIILJLH-UHFFFAOYSA-N 0.000 description 2
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
WDJKAQCAPHSOIO-UHFFFAOYSA-N 1-phenyl-3,6-dihydro-2h-pyridine Chemical compound C1C=CCCN1C1=CC=CC=C1 WDJKAQCAPHSOIO-UHFFFAOYSA-N 0.000 description 2
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 2
108091005479 5-HT2 receptors Proteins 0.000 description 2
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
229920002873 Polyethylenimine Polymers 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
239000003875 Wang resin Substances 0.000 description 2
NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
230000027455 binding Effects 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
210000005080 cortical synaptosome Anatomy 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
239000012954 diazonium Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229960002866 duloxetine Drugs 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000003365 glass fiber Substances 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000001690 micro-dialysis Methods 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
238000001050 pharmacotherapy Methods 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
125000003107 substituted aryl group Chemical group 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
FHYAUNJNVMGZQN-NHCUHLMSSA-N (2r,3r)-5-iodo-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1CN([C@@H]2CC3=C(I)C=CC=C3C[C@H]2O)CCC1C1=CC=CC=C1 FHYAUNJNVMGZQN-NHCUHLMSSA-N 0.000 description 1
125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
QVJYFDIAZOMESF-UHFFFAOYSA-N 1-bromo-2-(4-chlorophenyl)sulfanylbenzene Chemical compound C1=CC(Cl)=CC=C1SC1=CC=CC=C1Br QVJYFDIAZOMESF-UHFFFAOYSA-N 0.000 description 1
MPEOPBCQHNWNFB-UHFFFAOYSA-N 1-chloro-2-iodobenzene Chemical compound ClC1=CC=CC=C1I MPEOPBCQHNWNFB-UHFFFAOYSA-N 0.000 description 1
YUQUNWNSQDULTI-UHFFFAOYSA-N 2-bromobenzenethiol Chemical compound SC1=CC=CC=C1Br YUQUNWNSQDULTI-UHFFFAOYSA-N 0.000 description 1
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-n-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 description 1
NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
TWNHYHUUTGSBCB-UHFFFAOYSA-N 4-(2-phenylsulfanylphenyl)-1,2,3,6-tetrahydropyridine Chemical class C1NCCC(C=2C(=CC=CC=2)SC=2C=CC=CC=2)=C1 TWNHYHUUTGSBCB-UHFFFAOYSA-N 0.000 description 1
GCQFBLRJZDCZEK-UHFFFAOYSA-N 4-[2-(2,4,6-trimethylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC(C)=CC(C)=C1SC1=CC=CC=C1C1=CCNCC1 GCQFBLRJZDCZEK-UHFFFAOYSA-N 0.000 description 1
RBQOFTIAPCLINL-UHFFFAOYSA-N 4-[2-(2-chloro-4-methoxyphenyl)sulfanyl-5-fluorophenyl]-1,2,3,6-tetrahydropyridine Chemical compound ClC1=CC(OC)=CC=C1SC1=CC=C(F)C=C1C1=CCNCC1 RBQOFTIAPCLINL-UHFFFAOYSA-N 0.000 description 1
JKZIVROKOGUVQP-UHFFFAOYSA-N 4-[2-(2-methoxy-5-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound COC1=CC=C(C)C=C1SC1=CC=CC=C1C1=CCNCC1 JKZIVROKOGUVQP-UHFFFAOYSA-N 0.000 description 1
XBODOAHDRZCFPN-UHFFFAOYSA-N 4-[2-(2-methoxyphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound COC1=CC=CC=C1SC1=CC=CC=C1C1=CCNCC1 XBODOAHDRZCFPN-UHFFFAOYSA-N 0.000 description 1
YAVOBUWVFTXGQH-UHFFFAOYSA-N 4-[2-(2-methylphenyl)sulfanylphenyl]piperidin-4-ol Chemical compound CC1=CC=CC=C1SC1=CC=CC=C1C1(O)CCNCC1 YAVOBUWVFTXGQH-UHFFFAOYSA-N 0.000 description 1
GZJGOLWNJKWIFG-UHFFFAOYSA-N 4-[2-(3,4-dichlorophenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=C(Cl)C(Cl)=C1 GZJGOLWNJKWIFG-UHFFFAOYSA-N 0.000 description 1
YFPWBRPRMAYQAQ-UHFFFAOYSA-N 4-[2-(3-chloro-2-fluorophenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=CC(Cl)=C1F YFPWBRPRMAYQAQ-UHFFFAOYSA-N 0.000 description 1
GIEGWJVBVKIFKN-UHFFFAOYSA-N 4-[2-(3-chlorophenyl)sulfanyl-5-fluorophenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(F)=CC=C1SC1=CC=CC(Cl)=C1 GIEGWJVBVKIFKN-UHFFFAOYSA-N 0.000 description 1
NQLRPJLAQBSPIC-UHFFFAOYSA-N 4-[2-(3-fluoro-4-methylphenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(C)=CC=C1SC1=CC=C(C)C(F)=C1 NQLRPJLAQBSPIC-UHFFFAOYSA-N 0.000 description 1
LJIDQQITESAHJB-UHFFFAOYSA-N 4-[2-(4-chloro-2-fluorophenyl)sulfanyl-5-fluorophenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1CNCCC=1C1=CC(F)=CC=C1SC1=CC=C(Cl)C=C1F LJIDQQITESAHJB-UHFFFAOYSA-N 0.000 description 1
MSWYWNCHWRZBLX-UHFFFAOYSA-N 4-[2-(4-chloro-2-methylphenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC(Cl)=CC=C1SC1=CC=CC=C1C1=CCNCC1 MSWYWNCHWRZBLX-UHFFFAOYSA-N 0.000 description 1
XMMHCGDMNDVYBY-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)sulfanylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(Cl)=CC=C1SC1=CC=CC=C1C1=CCNCC1 XMMHCGDMNDVYBY-UHFFFAOYSA-N 0.000 description 1
AEFCDVXGWWUALM-UHFFFAOYSA-N 4-[2-(4-fluoro-3-methoxyphenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C1=C(F)C(OC)=CC(SC=2C(=CC(C)=CC=2)C=2CCNCC=2)=C1 AEFCDVXGWWUALM-UHFFFAOYSA-N 0.000 description 1
PEAKOCRRNYDZDS-UHFFFAOYSA-N 4-[2-(4-methoxy-2-methylphenyl)sulfanyl-5-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC(OC)=CC=C1SC1=CC=C(C)C=C1C1=CCNCC1 PEAKOCRRNYDZDS-UHFFFAOYSA-N 0.000 description 1
CHFKDBYGMYFRGW-UHFFFAOYSA-N 4-[2-(4-methylphenyl)sulfanyl-5-(trifluoromethyl)phenyl]piperidin-4-ol Chemical compound C1=CC(C)=CC=C1SC1=CC=C(C(F)(F)F)C=C1C1(O)CCNCC1 CHFKDBYGMYFRGW-UHFFFAOYSA-N 0.000 description 1
KYTPTLVWKZIXSG-UHFFFAOYSA-N 4-hydroxy-4-(2-sulfanylphenyl)piperidine-1-carboxylic acid Chemical compound OC1(CCN(CC1)C(=O)O)C1=C(C=CC=C1)S KYTPTLVWKZIXSG-UHFFFAOYSA-N 0.000 description 1
FOWOXWLATUAFNQ-UHFFFAOYSA-N 4-oxopiperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(=O)CC1 FOWOXWLATUAFNQ-UHFFFAOYSA-N 0.000 description 1
229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 1
MYLBTCQBKAKUTJ-UHFFFAOYSA-N 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine Chemical compound C1=CN=CC2=C(SC)C(C)=C(SC)N21 MYLBTCQBKAKUTJ-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102000007527 Autoreceptors Human genes 0.000 description 1
108010071131 Autoreceptors Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
240000008187 Erythrina edulis Species 0.000 description 1
235000002757 Erythrina edulis Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000948268 Meda Species 0.000 description 1
NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
206010041247 Social fear Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
150000001499 aryl bromides Chemical class 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125961 compound 24 Drugs 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000006193 diazotization reaction Methods 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000002635 electroconvulsive therapy Methods 0.000 description 1
239000012039 electrophile Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000005558 fluorometry Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
239000007943 implant Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
229910052808 lithium carbonate Inorganic materials 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
239000004050 mood stabilizer Substances 0.000 description 1
229940127237 mood stabilizer Drugs 0.000 description 1
230000008450 motivation Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960003057 nialamide Drugs 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920000307 polymer substrate Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000004544 sputter deposition Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229950002139 talsupram Drugs 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
JDXHOOVUGZTNEH-UHFFFAOYSA-N tert-butyl 2-oxopiperidine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1CCCNC1=O JDXHOOVUGZTNEH-UHFFFAOYSA-N 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
229940035722 triiodothyronine Drugs 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
229960004688 venlafaxine Drugs 0.000 description 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

UAA200508779A 2003-04-04 2004-02-04 Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture UA81300C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200300518		2003-04-04
PCT/DK2004/000243 WO2004087662A1 (en)	2003-04-04	2004-04-02	4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors

Publications (1)

Publication Number	Publication Date
UA81300C2 true UA81300C2 (en)	2007-12-25

Family

ID=35432910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200508779A UA81300C2 (en)	2003-04-04	2004-02-04	Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture

Country Status (27)

Country	Link
US (1)	US20070173522A1 (de)
EP (1)	EP1613594B1 (de)
JP (1)	JP2006522029A (de)
KR (1)	KR20060021825A (de)
CN (1)	CN100384822C (de)
AR (1)	AR043964A1 (de)
AT (1)	ATE390413T1 (de)
AU (1)	AU2004226319A1 (de)
BR (1)	BRPI0408453A (de)
CA (1)	CA2521172A1 (de)
CL (1)	CL2004000730A1 (de)
CO (1)	CO5700777A2 (de)
DE (1)	DE602004012724T2 (de)
DK (1)	DK1613594T3 (de)
EA (1)	EA009282B1 (de)
ES (1)	ES2301979T3 (de)
HR (1)	HRP20080243T3 (de)
IS (1)	IS8007A (de)
MX (1)	MXPA05010678A (de)
NO (1)	NO20055205L (de)
NZ (1)	NZ541944A (de)
PL (1)	PL1613594T3 (de)
PT (1)	PT1613594E (de)
SI (1)	SI1613594T1 (de)
UA (1)	UA81300C2 (de)
WO (1)	WO2004087662A1 (de)
ZA (1)	ZA200507182B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004087156A1 (en)	2003-04-04	2004-10-14	H. Lundbeck A/S	4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
JP5173190B2 (ja)	2004-08-25	2013-03-27	武田薬品工業株式会社	腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
EP2727585A1 (de)	2006-05-16	2014-05-07	Takeda Pharmaceutical Company Limited	In-vivo Screening-Methode
EP2789338A3 (de)	2007-11-15	2015-01-14	Takeda Pharmaceutical Company Limited	Kondensiertes Pyridinderivat und seine Verwendung
UA98698C2 (en) *	2008-03-03	2012-06-11	Х. Луннбек А/С	Phenylsulfanylphenyl-piperidines and process for the preparation thereof
EP2510949A4 (de)	2009-12-11	2013-11-13	Astellas Pharma Inc	Therapeutikum für fibromyalgie
EP2930171A1 (de) *	2014-04-07	2015-10-14	LEK Pharmaceuticals d.d.	Synthese von Vortioxetin über (2,4-Dimethylphenyl) (2-Iodophenyl)sulfan-Zwischenprodukt
CN105294554B (zh) *	2015-11-18	2017-11-07	乳源瑶族自治县大众药品贸易有限公司	苯基哌嗪衍生物及其使用方法和用途
US20210052600A1 (en)	2017-12-27	2021-02-25	Takeda Pharmaceutical Company Limited	Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3803143A (en) *	1969-09-08	1974-04-09	Eisai Co Ltd	6-amino alkylene 6,7-dihydro-5h-dibenzo (b,g),(1,5)thiazocines
US4018830A (en) *	1969-09-22	1977-04-19	Merck & Co., Inc.	Phenylthioaralkylamines
US4055665A (en) *	1974-11-25	1977-10-25	Merck & Co., Inc.	Treating arrythmia with phenylthioaralkylamines
US4066654A (en) *	1975-04-16	1978-01-03	G. D. Searle & Co.	1-triarylalkyl-4-phenyl-4-piperidine carboxylic acids and derivatives
US4056632A (en) *	1975-07-21	1977-11-01	Burroughs Wellcome Co.	2-Hydroxymethyl-2'-aminomethyl-diphenylsulfides and method of use
DE2802306A1 (de) *	1977-01-27	1978-08-10	Hoechst Ag	Azacycloalkane, azacycloalkene und ihre derivate
US4241071A (en) *	1977-01-27	1980-12-23	American Hoechst Corporation	Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198419A (en) *	1979-01-10	1980-04-15	American Hoechst Corporation	Phenylthiophenylpiperidines
US4198417A (en) *	1979-01-10	1980-04-15	American Hoechst Corporation	Phenoxyphenylpiperidines
GB8912971D0 (en) *	1989-06-06	1989-07-26	Wellcome Found	Halogen substituted diphenylsulfides
WO2001027068A1 (en) *	1999-10-13	2001-04-19	Pfizer Products Inc.	Biaryl ether derivatives useful as monoamine reuptake inhibitors
US6410736B1 (en) *	1999-11-29	2002-06-25	Pfizer Inc.	Biaryl ether derivatives useful as monoamine reuptake inhibitors
ATE261959T1 (de) *	1999-12-30	2004-04-15	Lundbeck & Co As H	Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
US6436938B1 (en) *	2001-01-22	2002-08-20	Pfizer Inc.	Combination treatment for depression
US20020107244A1 (en) *	2001-02-02	2002-08-08	Howard Harry R.	Combination treatment for depression
UA81749C2 (uk) *	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну

2004
- 2004-02-04 UA UAA200508779A patent/UA81300C2/uk unknown
- 2004-04-02 CA CA002521172A patent/CA2521172A1/en not_active Abandoned
- 2004-04-02 AU AU2004226319A patent/AU2004226319A1/en not_active Abandoned
- 2004-04-02 DE DE602004012724T patent/DE602004012724T2/de not_active Expired - Fee Related
- 2004-04-02 MX MXPA05010678A patent/MXPA05010678A/es active IP Right Grant
- 2004-04-02 DK DK04725299T patent/DK1613594T3/da active
- 2004-04-02 BR BRPI0408453-5A patent/BRPI0408453A/pt not_active IP Right Cessation
- 2004-04-02 CN CNB2004800094713A patent/CN100384822C/zh not_active Expired - Fee Related
- 2004-04-02 ZA ZA200507182A patent/ZA200507182B/en unknown
- 2004-04-02 JP JP2006504348A patent/JP2006522029A/ja active Pending
- 2004-04-02 HR HR20080243T patent/HRP20080243T3/xx unknown
- 2004-04-02 EA EA200501579A patent/EA009282B1/ru not_active IP Right Cessation
- 2004-04-02 WO PCT/DK2004/000243 patent/WO2004087662A1/en not_active Ceased
- 2004-04-02 AR ARP040101130A patent/AR043964A1/es not_active Application Discontinuation
- 2004-04-02 ES ES04725299T patent/ES2301979T3/es not_active Expired - Lifetime
- 2004-04-02 US US10/551,869 patent/US20070173522A1/en not_active Abandoned
- 2004-04-02 PL PL04725299T patent/PL1613594T3/pl unknown
- 2004-04-02 KR KR1020057018870A patent/KR20060021825A/ko not_active Withdrawn
- 2004-04-02 SI SI200430727T patent/SI1613594T1/sl unknown
- 2004-04-02 PT PT04725299T patent/PT1613594E/pt unknown
- 2004-04-02 EP EP04725299A patent/EP1613594B1/de not_active Expired - Lifetime
- 2004-04-02 CL CL200400730A patent/CL2004000730A1/es unknown
- 2004-04-02 NZ NZ541944A patent/NZ541944A/en unknown
- 2004-04-02 AT AT04725299T patent/ATE390413T1/de not_active IP Right Cessation
2005
- 2005-08-29 IS IS8007A patent/IS8007A/is unknown
- 2005-11-02 CO CO05111852A patent/CO5700777A2/es unknown
- 2005-11-04 NO NO20055205A patent/NO20055205L/no unknown

Also Published As

Publication number	Publication date
NO20055205L (no)	2005-11-04
PT1613594E (pt)	2008-07-01
WO2004087662A1 (en)	2004-10-14
MXPA05010678A (es)	2005-12-12
DE602004012724D1 (de)	2008-05-08
EA200501579A1 (ru)	2006-04-28
EP1613594B1 (de)	2008-03-26
KR20060021825A (ko)	2006-03-08
ES2301979T3 (es)	2008-07-01
BRPI0408453A (pt)	2006-04-04
EA009282B1 (ru)	2007-12-28
DE602004012724T2 (de)	2009-04-09
ATE390413T1 (de)	2008-04-15
US20070173522A1 (en)	2007-07-26
IS8007A (is)	2005-08-29
CL2004000730A1 (es)	2005-02-18
CN1777585A (zh)	2006-05-24
EP1613594A1 (de)	2006-01-11
PL1613594T3 (pl)	2008-09-30
CA2521172A1 (en)	2004-10-14
HK1090051A1 (en)	2006-12-15
ZA200507182B (en)	2006-12-27
CO5700777A2 (es)	2006-11-30
AU2004226319A1 (en)	2004-10-14
CN100384822C (zh)	2008-04-30
JP2006522029A (ja)	2006-09-28
SI1613594T1 (sl)	2008-08-31
HRP20080243T3 (hr)	2009-04-30
DK1613594T3 (da)	2008-07-14
AR043964A1 (es)	2005-08-17
NZ541944A (en)	2008-05-30

Publication	Publication Date	Title
RU2262504C2 (ru)	2005-10-20	Замещенные 4-(фенил-n-алкил)пиперидины, фармацевтическая композиция на их основе и способы лечения
JP6359560B2 (ja)	2018-07-18	複素環式化合物及びその使用方法
CA2852355C (en)	2019-12-31	(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
UA79782C2 (en)	2007-07-25	[1,4]diazepino[6,7,1-ij]quinoline derivatives as anti psychotic and antiobesity agents
TW202430504A (zh)	2024-08-01	Ｋ他命的前藥及其組成物及用途
JP2010184946A (ja)	2010-08-26	中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物
ES2734734T3 (es)	2019-12-11	Compuestos de amida como agonistas del receptor 5-HT4
CA2804165C (en)	2015-02-24	Piperidinyl pyrimidine amides as kv7 potassium channel openers
EP3450428A1 (de)	2019-03-06	Substituierte benzamide und verfahren zur verwendung davon
CA3008614A1 (en)	2017-06-22	Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CN115850361A (zh)	2023-03-28	C7取代的氧固醇及其作为nmda调节剂的方法
JP5369108B2 (ja)	2013-12-18	受動拡散型ヌクレオシド輸送体ｅｎｔ１阻害剤
UA81300C2 (en)	2007-12-25	Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
EP2560974B1 (de)	2016-01-27	Pyrrazolopyridin-derivate
CA2462861A1 (en)	2003-04-17	Piperidine compounds as muscarinic antagonists
ES2303062T3 (es)	2008-08-01	Derivados de 4-(2-feniloxifenil)-piperidina o 1,2,3,6-tetrahidropiridina como inhibidores de la recaptura de serotonina.
CN101481323A (zh)	2009-07-15	苯并环庚烯类衍生物、其制备方法及医药用途
EP2828238B1 (de)	2016-05-25	Sulfonamidderivate von benzylamin zur behandlung von zns-erkrankungen
EP1747221B1 (de)	2009-07-01	Nk1-antagonisten mit kondensiertem ring
JP6493711B2 (ja)	2019-04-03	ナトリウムチャネル関連疾患及び障害の治療におけるテトラヒドロピリジンの使用
TW202547576A (zh)	2025-12-16	取代磺醯胺巨環狀化合物
UA80190C2 (en)	2007-08-27	Sustituted indoline and indole derivatives
EA012752B1 (ru)	2009-12-30	Производные 2-(1н-индолилсульфанил)бензиламина в качестве ssri
JP2012504574A (ja)	2012-02-23	Ｍ１受容体において活性を有する化合物およびその医薬における使用
CN118284607A (zh)	2024-07-02	用于治疗疾病和障碍的lsd衍生物、合成和方法